Roche

Roche reports positive results for crovalimab as rare blood disease treatment

Roche has announced positive results from its phase 3 study of crovalimab in patients with paroxysmal nocturnal haemoglobinuria (PNH), a rare and life threatening blood condition. ... People with PNH may benefit from more options to achieve robust

Roche’s Polivy recommended by NICE for lymphoma therapy

Roche’s Polivy (polatuzumab vedotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a drug combination to treat adults with an aggressive form ... We are delighted with today’s news that patients in

Pistoia Alliance launches free guide on implementing FAIR principles in clinical data

The guide was co-authored by leading experts from Roche, AstraZeneca and others. ... The guide was co-authored by the Pistoia Alliance and leading experts in the field, which included AstraZeneca, Roche, Bayer, Genentech, Galapagos, the Hyve, Elixir, the

Genentech reports positive phase 3 data for its Tecentriq combination in liver cancer

Tecentriq in combination with Avastin significantly improved recurrence-free survival. Genentech – a member of the Roche group – has announced that its phase 3 study of Tecentriq (atezolizumab) combination mets its primary ... Levi Garraway,

World Health Organization releases latest set of COVID-19 guidelines

WHO also reviewed the evidence on two other medicines, GSK/Vir Biotechnology’s Xevudy (sotrovimab) and Regeneron/Roche’s REGEN-COV (casirivimab/imdevimab), and maintains strong recommendations against their use for

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]